CI

CIGNA
D

CI

Arincen60/100B

If you had invested in CIGNA ago, it would be worth $2,466 today, against $4,096 in SPY and $6,368 in QQQ.

ArincenArincen ScoreBeta

60/100

Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.

Profitability2

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Cash6

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Valuation10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Growth8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Financial strength2

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Shareholders8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Figures to FY2025; the price as of today.

CIGNA key facts

Style
Value stock · 8.9/10Growth 4.7 · Value 8.9 · Dividend 5.2
Day range
293.45 – 297.81
52-week range
256.52 – 318.05
Market capitalization
77.63B USD
P/E
12.97
PEG ratio
0.88
EPS
22.72
Div Yield
2.12%
EPS growth forecast (FY2026)
+2.6%
Volume
7,693
Beta
0.30
ESG score
63.9/100Environment 66 · Social 55 · Governance 71
Sector
Healthcare
Industry
Medical - Healthcare Plans
CEO
Brian C. Evanko
Employees
67K
IPO date
31 Mar 1982

CIGNA earnings

Next earnings · Q4 FY2026
EPS estimate
7.18 USD
Revenue estimate
74.90B USD
Last quarter · Q3 FY2026
EPS7.98Beat +6.1%Revenue73.68BBeat +1.4%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q3 FY20278.53——+6.85%76.00B——+3.14%
Q2 FY20278.48——+9.05%73.82B——+3.00%
Q1 FY20278.35——+7.18%71.48B——+4.35%
Q4 FY20267.18——-11.14%74.90B——+3.35%
Q3 FY20267.527.98+6.12%+1.92%72.64B73.68B+1.44%+5.64%
Q2 FY20267.607.78+2.37%+8.06%70.14B71.67B+2.17%+6.60%
Q1 FY20267.607.79+2.50%+15.58%66.29B68.49B+3.32%+4.57%
Q4 FY20257.888.08+2.54%+21.69%70.31B72.47B+3.08%+10.28%
Q3 FY20257.647.83+2.49%+4.26%67.58B69.75B+3.21%+11.11%
Q2 FY20257.167.20+0.56%+7.14%62.91B67.23B+6.87%+11.17%

Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved

CIGNA analyst forecast

12-month price target
343.46 USD
+16.59%

Analysts' 1-year price targets range from 302.00 to 400.00, with an average of 343.46.

Past year
1-year forecast
Strong sellStrong buy
Buy
16 ratings
Buy
11
Hold
5
Sell
0

12-month price target

Highest target400.00
Average target343.46
Lowest target302.00
Current price294.60

CIGNA valuation

Price to earnings ratio (TTM)
12.97
Forward P/E (FY2026)
9.61
Price to sales (TTM)
0.27
Price to book
1.79
EV / EBITDA (TTM)
8.10

Capital structure

Market capitalization
77.63B USD
+
Total debt
31.14B USD
−
Cash and short-term investments
7.30B USD
=
Enterprise value
101.47B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)8.01————
FY2027 (est.)8.858.01———
FY2026 (est.)9.618.85———
Now (TTM)12.978.940.271.798.10
FY202512.348.980.271.758.25
FY202422.5413.340.311.898.17
FY202317.0413.340.461.929.28
FY202215.3013.340.572.3111.23
FY202114.4511.000.451.659.63

CIGNA against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Elevance Health, CVS Health, Humana, Centene, UnitedHealth Group, and Molina Healthcare, the US Medical - Healthcare Plans companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Below its median13.0
    9.129.4
  • Gross marginLowest in 5 years9.5%
    9.5%13.2%
    Against its peers: 6 of 7Peers' median 14.2%
  • Operating marginLowest in 5 years3.3%
    3.3%4.7%
    Against its peers: 3 of 7Peers' median 2.2%
  • Net marginBelow its median2.2%
    1.4%3.7%
    Against its peers: 3 of 7Peers' median 1.0%
  • Return on equityAbove its median14.3%
    8.4%14.9%
    Against its peers: 1 of 7Peers' median 9.2%
  • Free cash flow marginLowest in 5 years3.1%
    3.1%5.2%
    Against its peers: 2 of 7Peers' median 1.8%
  • Revenue growthAbove its median11.3%
    3.7%26.6%
    Against its peers: 5 of 7Peers' median 11.8%
  • EPS growthHighest in 5 years82.9%
    -31.4%82.9%
    Against its peers: 1 of 7Peers' median -35.5%
  • Debt to EBITDAAt its median2.68×
    2.56×3.09×
    Against its peers: 1 of 6Peers' median 4.05×
  • Current ratioHighest in 5 years0.85
    0.730.85
    Against its peers: 4 of 7Peers' median 1.04

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

CIGNA growth and profitability

Revenue (TTM)
286.32B USD
Net income (TTM)
5.99B USD
Gross margin
10.26%
Operating margin
3.35%
Net margin
2.09%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY2025274.95B+11.26%5.96B+73.47%9.45%3.32%2.17%11.75B-5.76%
FY2024247.12B+26.56%3.43B-33.50%10.51%3.81%1.39%12.47B+3.30%
FY2023195.27B+8.17%5.16B-22.97%12.89%4.37%2.64%12.07B+4.80%
FY2022180.52B+3.70%6.70B+24.84%13.02%4.68%3.71%11.52B+3.89%
FY2021174.07B+8.52%5.37B-36.51%13.19%4.56%3.08%11.09B-2.48%

CIGNA revenue breakdown

By product

FY2025
Evernorth: 83.2%Cigna Healthcare: 16.8%83.2%Evernorth16.8%Cigna Healthcare
SegmentRevenueShare of revenueChange on the year
Evernorth234.95B83.2%+18.6%
Cigna Healthcare47.41B16.8%-0.2%

By region

FY2024
100.0%United States
RegionRevenueShare of revenueChange on the year
United States241.56B100.0%+27.2%

How CIGNA makes its money

Revenue274.95B 100.0%
Cost of revenue248.97B 90.5%
Gross profit25.99B 9.5%
Selling and administration14.00B 5.1%
Other operating expenses2.86B 1.0%
Operating income9.13B 3.3%
Tax1.35B 0.5%
Other expense1.83B 0.7%
Net income5.96B 2.2%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

CIGNA dividends

Annual dividend
6.24 USD
Dividend yield (indicated)
2.12%
Payout ratio
34.11%
Years of dividend growth
6
Frequency
Quarterly
Next payment
1.56 USD
Next ex-dividend date
3 Dec 2026
Next payment date
17 Dec 2026

Dividends per share

Year2025202420232022202120202019201820172016
Dividends per share6.045.604.924.484.000.040.040.040.040.04

CIGNA financial health

Cash and short-term investments
7.30B USD
Total debt
31.14B USD
Net cash
-23.85B USD
Free cash flow (TTM)
8.27B USD
Current ratio
0.84
Debt to equity
0.72
Piotroski score
8 / 9
Altman Z-score
2.82

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY20257.68B31.46B8.39B
FY20248.22B31.97B8.96B
FY20238.75B30.93B10.24B
FY20226.83B31.55B7.36B
FY20216.00B34.27B6.04B

CIGNA ownership

Institutions
91.21%
Institutional holders
1,770 (+44)
Free float
99.50%

Who owns the shares

Institutions 91.2% Others 8.8%
As of 30 Jun 2026

Shares free to trade

Free float 262.20M shares ·99.5% Closely held 1.30M shares ·0.5%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q3 20260325.29K38.08K
Q2 2026014221.37K416.22K
Q1 202602159.01K29.12K
Q4 20251110.51K11.64K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025265.95M265.95M-6.10%
FY2024280.29M283.22M-4.60%
FY2023296.88M296.88M-5.17%
FY2022313.07M313.07M-8.18%
FY2021337.96M340.97M-7.44%

Source: Financial Modeling Prep

Related Instruments

Title: Cigna Group (The)

Sector: Healthcare
Industry: Medical - Healthcare Plans
Cigna Corporation is an American health services conglomerate that offers medical as well as dental insurance and related products and services. The company was founded in 1792 and is based in Bloomfield, Connecticut. The Company's segments include Evernorth and Cigna Healthcare. The former offers a coordinated combination of pharmacy solutions, benefits management solutions, care delivery and care management solutions, and intelligence solutions. The latter caters to US Commercial, US Government and International Health operating segments, which provide a range of medical and coordinated solutions to clients and customers to support whole-person health needs. The company has consistently been ranked in the top 20 of the list of Fortune 500 largest US corporations by total revenue.

Common questions about CIGNA stock